U.S. drugmaker Eli Lilly and Co said on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.
FILE PHOTO: Eli Lilly logo is shown on one of the company's offices in San Diego, California, U.S., September 17, 2020. REUTERS/Mike Blakesaid on Tuesday that the government-sponsored clinical trial of its COVID-19 antibody treatment has been paused because of a safety concern.
“Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board has recommended a pause in enrollment,” Lilly spokeswoman Molly McCully said in an emailed statement. “Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety of the patients participating in this study.”treatment President Donald Trump received after he contracted COVID-19.
Lilly had already asked U.S. regulators to authorize its antibody therapy, LY-CoV555, for emergency use after publishing data in September showing it helped cut hospitalization and emergency room visits for COVID-19 patients. The treatment is being developed with Canadian biotech AbCellera.Our Standards:
United States Latest News, United States Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Eli Lilly antibody trial paused due to potential safety concern"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety
Read more »
Eli Lilly pauses trial of its monoclonal antibody to treat Covid-19 for safety reasonsThe coronavirus pandemic has brought countries to a standstill. In many places, as countries reopen, Covid-19 cases are on the rise. Follow here for the latest.
Read more »
U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns
Read more »
Eli Lilly antibody trial paused due to potential safety concern"Out of an abundance of caution, the ACTIV-3 independent data safety monitoring board (DSMB) has recommended a pause in enrollment," Lilly spokeswoman Molly McCully said in an emailed statement. "Lilly is supportive of the decision by the independent DSMB to cautiously ensure the safety
Read more »
U.S. pauses Eli Lilly's trial of a coronavirus antibody treatment over safety concerns
Read more »
Eli Lilly pauses trial of its monoclonal antibody to treat Covid-19 for safety reasonsThe coronavirus pandemic has brought countries to a standstill. In many places, as countries reopen, Covid-19 cases are on the rise. Follow here for the latest.
Read more »